|
[1] Chinese Society of Hepatology,Chinese Medical Association;Chinese Society of Gastroenterology,Chinese Medical Association; Chinese Society of Infectious Diseases,Chinese Medical Association. Consensus on the diagnosis and management of autoimmune hepatitis(2015)[J]. J Clin Hepatol,2016,32(1):9-22.(in Chinese)中华医学会肝病学分会，中华医学会消化病学分会，中华医学会感染病学分会．自身免疫性肝炎诊断和治疗共识(2015)[J]．临床肝胆病杂志，2016,32(1):9-22.
|
|
[2] European Association for the Study of the Liver. EASL-autoimmune hepatitis-clinical practice guideline[J]. J Hepatol,2015,63(4):971-1004.
|
|
[3] MACK CL,ADAMS D,ASSIS DN,et al. Diagnosis and management of autoimmune hepatitis in adults and children:2019practice guidance and guidelines from the American Association for the study of liver diseases[J]. Hepatology,2019.[Epub ahead of print]
|
|
[4] Special Committee of Autoantibody Detection,Chinese Association of Rheumatology&Immunology Physicians, Chinese Medical Doctor Association. Expert consensus on the clinical application of antinuclear antibody[J]. Chin J Lab Med,2018,41(4):275-280.(in Chinese)中国医师协会风湿免疫科医师分会自身抗体检测专业委员会．抗核抗体检测的临床应用专家共识[J]．中华检验医学杂志，2018,41(4):275-280.
|
|
[5] CHAN EK,DAMOISEAUX J,CARBALLO OG,et al. Report of the first international consensus on standardized nomenclature of antinuclear antibody HEp-2 cell patterns 2014-2015[J].Front Immunol,2015,6:412.
|
|
[6] MIELI-VERGANI G,VERGANI D,CZAJA AJ,et al. Autoimmune hepatitis[J]. Nat Rev Dis Primers,2018,4:18017.
|
|
[7] European Association for the Study of the Liver. EASL clinical practice guidelines:The diagnosis and management of patients with primary biliary cholangitis[J]. J Hepatol,2017,67(1):145-172.
|
|
[8] ALVAREZ F,BERG PA,BIANCHI FB,et al. International autoimmune hepatitis group report:Review of criteria for diagnosis of autoimmune hepatitis[J]. J Hepatol,1999,31(5):929-938.
|
|
[9] HENNES EM,ZENIYA M,CZAJA AJ,et al. Simplified criteria for the diagnosis of autoimmune hepatitis[J]. Hepatology,2008,48(1):169-176.
|
|
[10] YAN HP,JIA JD. Autoimmune liver disease[M]. Beijing:People’s Medical Publishing House,2018.(in Chinese)闫惠平，贾继东．自身免疫性肝脏疾病[M]．北京:人民卫生出版社，2018.
|
|
[11] TERZIROLI BERETTA-PICCOLI B,MIELI-VERGANI G,VERGANI D. Serology in autoimmune hepatitis:A clinical-practice approach[J]. Eur J Intern Med,2018,48:35-43.
|
|
[12] SHIBUKI T,OTSUKA T,ISODA H,et al. Seropositivity and titers of anti-smooth muscle actin antibody are associated with relapse of type 1 autoimmune hepatitis[J]. Med Sci Monit,2017,23:4028-4033.
|
|
[13] COUTO CA,BITTENCOURT PL,PORTA G,et al. Antismooth muscle and antiactin antibodies are indirect markers of histological and biochemical activity of autoimmune hepatitis[J].Hepatology,2014,59(2):592-600.
|
|
[14] GUGUEN P,DALEKOS G,NOUSBAUM JB,et al. Double reactivity against actin and alpha-actinin defines a severe form of autoimmune hepatitis type 1[J]. J Clin Immunol,2006,26(6):495-505.
|
|
[15] ZACHOU K,OIKONOMOU K,RENAUDINEAU Y,et al. Anti-αactinin antibodies as new predictors of response to treatment in autoimmune hepatitis type 1[J]. Aliment Pharmacol Ther,2012,35(1):116-125.
|
|
[16] MANNS M,GERKEN G,KYRIATSOULIS A,et al. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen[J]. Lancet,1987,1(8528):292-294.
|
|
[17] WIES I,BRUNNER S,HENNINGER J,et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis[J]. Lancet,2000,355(9214):1510-1515.
|
|
[18] PALIOURA S,SHERRER RL,STEITZ TA,et al. The human SepSecS-tRNASec complex reveals the mechanism of selenocysteine formation[J]. Science,2009,325(5938):321-325.
|
|
[19] JOHANET C,BALLOT E. Auto-antibodies in autoimmune hepatitis:Anti-soluble liver antigen(SLA)[J]. Clin Res Hepatol Gastroenterol,2012,36(3):244-246.
|
|
[20] TERZIROLI BERETTA-PICCOLI B,MIELI-VERGANI G,VERGANI D. The clinical usage and definition of autoantibodies in immune-mediated liver disease:A comprehensive overview[J]. J Autoimmun,2018,95:144-158.
|
|
[21] ZHAGN HP,MA YX,LI LJ,et al. Analysis of the autoantibodies characteristics of 77 anti-soluble liver antigen positive patients with liver diseases[J]. Chin J Lab Med,2019,42(11):927-932.(in Chinese)张海萍，马胤雪，李丽娟，等．77例抗可溶性肝抗原抗体阳性肝病患者的自身抗体特征分析[J]．中华检验医学杂志，2019,42(11):927-932.
|
|
[22] ZACHOU K,WEILER-NORMANN C,MURATORI L,et al.Permanent immunosuppression in SLA/LP-positive autoimmune hepatitis is required although overall response and survival are similar[J]. Liver Int,2020,40(2):368-376.
|
|
[23] CHEN ZX,SHAO JG,SHEN Y,et al. Prognostic implications of antibodies to soluble liver antigen in autoimmune hepatitis:A PRISMA-compliant meta-analysis[J]. Medicine(Baltimore),2015,94(23):e953.
|
|
[24] MONTANO-LOZA AJ,SHUMS Z,NORMAN GL,et al. Prognostic implications of antibodies to Ro/SSA and soluble liver antigen in type 1 autoimmune hepatitis[J]. Liver Int,2012,32(1):85-92.
|
|
[25] LONGHI MS,HUSSAIN MJ,BOGDANOS DP,et al. Cytochrome P450IID6-specific CD8 T cell immune responses mirror disease activity in autoimmune hepatitis type 2[J]. Hepatology,2007,46(2):472-484.
|
|
[26] GORDON V,ADHIKARY R,APPLEBY V,et al. Diagnosis,presentation and initial severity of autoimmune hepatitis(AIH)in patients attending 28 hospitals in the UK[J]. Liver Int,2018,38(9):1686-1695.
|
|
[27] HAN Y,YAN HP,LIAO HY,et al. Clinical value of anti-liver/kidney microsomal-1 antibody in patients with liver disease[J]. Chin J Hepatol,2017,25(11):852-857.(in Chinese)韩莹，闫惠平，廖慧钰，等．抗肝肾微粒体抗体在肝病患者中的临床意义评价[J]．中华肝脏病杂志，2017,25(11):852-857.
|
|
[28] CLEMENTE MG,ANTONUCCI R,MANDATO C,et al. Autoantibodies against CYP-2C19:A novel serum marker in pediatric de novo autoimmune hepatitis?[J]. Biomed Res Int,2017,2017:3563278.
|
DownLoad: